It is interesting that in the case of pancreatic NETs, the so-called “neuroendocrine tumors paradox” has been described, which was based on a higher expression of selected angiogenic factors, such as VEGF, in benign pancreatic neuroendocrine tumors, and was associated with a better prognosis [26]. This evidence concerns the gene VEGFA and pancreatic neuroendocrine tumor.